-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec content team On October 11, 2021, Aligos Therapeutics announced that ALG-020572 has completed the first patient administration in phase 1 clinical trial
.
It is an antisense oligonucleotide (ASO) in therapy research, through complementary binding to the mRNA, the interference from the transfer of genetic information to the protein of the nucleic acid, thereby reducing chronic HBV hepatitis B surface antigen (HBsAg) levels
.
The test consists of two parts
.
Part 1 will evaluate the safety, tolerability and pharmacokinetics of a single subcutaneous administration of ALG-020572 in healthy volunteers
.
In Part 2, the safety, pharmacokinetics, and antiviral activity of multiple subcutaneous administrations within 28 days will be evaluated in multiple subgroups of chronic hepatitis B patients
.
▲Aligos' research and development pipeline (picture source: Aligos official website) Aligos' research pipeline also includes S-antigen transport inhibitory oligonucleotide polymer (STOPS) molecules, capsid assembly regulators (CAMs) and small interfering RNA (siRNA) ) Candidate drugs
.
Their combined use may produce a potentially optimal treatment plan and obtain a higher functional cure rate than the current standard treatment
.
"This is our second paragraph to advance to the clinical development of drug candidates, can be targeted to reduce the chronic hepatitis B patients with HBsAg
.
"
Aligos Chairman and CEO Dr.
Lawrence Blatt said, "Our ASO molecules selectively seek and destroy the virus mRNA and use the third-generation XNA chemical design technology to improve the pharmacological properties of the molecule
.
We hope that these enhanced properties will improve the antiviral activity of the candidate drug in the clinic
.
"The principal investigator of a clinical trial, Professor Ed Gane added:" I believe that reducing HBsAg levels is a necessary step to achieve functional cure hepatitis
.
Other ASOs have been clinically proven to significantly reduce HBsAg
.
Given that ALG-020572 may have stronger antiviral activity than other ASOs, and the enhanced liver cell targeting effect through GalNAc, the combination regimen containing ALG-020572 is expected to achieve a higher functional cure rate
.
"As the application of ASO therapy becomes more and more widespread, WuXi AppTec subsidiary Hequan Pharmaceutical has also built an integrated CRDMO platform that includes ASO, siRNA, aptamer, microRNA, PMO and other innovative oligonucleotide drugs in recent years.
, Covering all material requirements from drug discovery to commercial production, helping the development of innovative oligonucleotide drugs
.
Reference materials: [1] Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study.
Retrieved October 11, 2021, from https://investor.
aligos.
com/news-releases/news-release-details/aligos-therapeutics-begins-dosing-antisense-oligonucleotide-drug : WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
.
It is an antisense oligonucleotide (ASO) in therapy research, through complementary binding to the mRNA, the interference from the transfer of genetic information to the protein of the nucleic acid, thereby reducing chronic HBV hepatitis B surface antigen (HBsAg) levels
.
The test consists of two parts
.
Part 1 will evaluate the safety, tolerability and pharmacokinetics of a single subcutaneous administration of ALG-020572 in healthy volunteers
.
In Part 2, the safety, pharmacokinetics, and antiviral activity of multiple subcutaneous administrations within 28 days will be evaluated in multiple subgroups of chronic hepatitis B patients
.
▲Aligos' research and development pipeline (picture source: Aligos official website) Aligos' research pipeline also includes S-antigen transport inhibitory oligonucleotide polymer (STOPS) molecules, capsid assembly regulators (CAMs) and small interfering RNA (siRNA) ) Candidate drugs
.
Their combined use may produce a potentially optimal treatment plan and obtain a higher functional cure rate than the current standard treatment
.
"This is our second paragraph to advance to the clinical development of drug candidates, can be targeted to reduce the chronic hepatitis B patients with HBsAg
.
"
Aligos Chairman and CEO Dr.
Lawrence Blatt said, "Our ASO molecules selectively seek and destroy the virus mRNA and use the third-generation XNA chemical design technology to improve the pharmacological properties of the molecule
.
We hope that these enhanced properties will improve the antiviral activity of the candidate drug in the clinic
.
"The principal investigator of a clinical trial, Professor Ed Gane added:" I believe that reducing HBsAg levels is a necessary step to achieve functional cure hepatitis
.
Other ASOs have been clinically proven to significantly reduce HBsAg
.
Given that ALG-020572 may have stronger antiviral activity than other ASOs, and the enhanced liver cell targeting effect through GalNAc, the combination regimen containing ALG-020572 is expected to achieve a higher functional cure rate
.
"As the application of ASO therapy becomes more and more widespread, WuXi AppTec subsidiary Hequan Pharmaceutical has also built an integrated CRDMO platform that includes ASO, siRNA, aptamer, microRNA, PMO and other innovative oligonucleotide drugs in recent years.
, Covering all material requirements from drug discovery to commercial production, helping the development of innovative oligonucleotide drugs
.
Reference materials: [1] Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study.
Retrieved October 11, 2021, from https://investor.
aligos.
com/news-releases/news-release-details/aligos-therapeutics-begins-dosing-antisense-oligonucleotide-drug : WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.